STOCK TITAN

Takeda Pharm - TAK STOCK NEWS

Welcome to our dedicated page for Takeda Pharm news (Ticker: TAK), a resource for investors and traders seeking the latest updates and insights on Takeda Pharm stock.

Takeda Pharmaceutical Company Limited (NYSE: TAK), a Japanese multinational corporation, stands as Asia's largest and one of the globe's top 20 pharmaceutical giants by revenue. Headquartered in Tokyo, Takeda operates across approximately 80 countries, merging American and British roots into its vast global presence.

With a revenue of JPY 4.3 trillion in fiscal 2023, Takeda dedicates its efforts predominantly to five therapeutic areas: oncology, gastroenterology, neuroscience, rare diseases, and plasma-derived therapies, which collectively generate more than 80% of its revenue. Takeda’s global footprint is diversified, with 50% of its revenue originating from the US, 20% from Japan, and another 20% from Europe and Canada.

Noteworthy for its robust pipeline and commitment to innovation, Takeda partners with various organizations to push the boundaries of medical research. A recent highlight includes a joint venture with Astellas Pharma Inc. and Sumitomo Mitsui Banking Corporation. This collaboration aims to incubate early drug discovery programs, striving to transition academic breakthroughs into practical medical treatments.

Moreover, Takeda's strategic partnership with Neurocrine Biosciences to develop NBI-1065845, an investigational treatment for major depressive disorder, showcases its dedication to addressing unmet medical needs. The positive Phase 2 results of the SAVITRI™ study underline the potential of NBI-1065845 to provide hope for patients with inadequate responses to existing treatments.

Takeda's philosophy focuses on creating a healthier world through life-transforming treatments in its core areas. Their values-based, R&D-driven approach has sustained their leadership in the pharmaceutical sector for over two centuries.

Rhea-AI Summary

Takeda reported its Q1 FY2022 financial results with core revenue growth of +8.3% at constant exchange rates (CER) and a core operating profit growth of +17%. Reported revenues reached 972.5 billion yen, representing a +2.4% rise, while the operating profit was 150.5 billion yen, down -39.4% due to a prior year one-time gain. Key business areas, particularly Growth & Launch Products, saw a significant revenue boost of +26% at CER. Takeda remains on track to meet its FY2022 management guidance amidst a challenging macroeconomic environment.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.82%
Tags
none
-
Rhea-AI Summary

Takeda announced that its Phase 3 clinical trial, ADVANCE-1, evaluating HYQVIA for chronic inflammatory demyelinating polyradiculoneuropathy (CIDP), met its primary endpoint. The treatment reduced relapse rates significantly compared to placebo (9.7% vs 31.4%; p-value = 0.0045). The trial involved 132 adult patients previously on IVIG therapy. Takeda plans to submit regulatory applications in the US and EU for HYQVIA in fiscal year 2022.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.59%
Tags
-
Rhea-AI Summary

Takeda Pharmaceutical Company Limited has submitted its Corporate Governance Report to the Tokyo Stock Exchange, adhering to TSE regulations. This report, rooted in the revised Corporate Governance Code effective as of June 11, 2021, highlights a diverse Board of Directors with a composition of 4 internal and 11 independent external directors. The report emphasizes increased transparency and independence in governance, with advisory committees staffed entirely by external directors. The full report can be accessed on Takeda’s website and the Japan Exchange Group’s platform.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.14%
Tags
none
Rhea-AI Summary

Takeda reported positive results from the Phase 3 SPRING study of TAKHZYRO, a treatment for hereditary angioedema (HAE) in children aged 2 to <12 years. The study demonstrated a 94.8% reduction in HAE attacks over 52 weeks compared to baseline. Notably, 76.2% of patients were attack-free during the treatment, with an average of 99.5% attack-free days. The results align with the efficacy and safety profile seen in adults. Takeda plans to initiate global regulatory filings in fiscal year 2022 to expand TAKHZYRO's indication for younger patients.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.36%
Tags
-
Rhea-AI Summary

Takeda (TAK) and Arrowhead Pharmaceuticals (NASDAQ: ARWR) announced promising results from the Phase 2 AROAAT-2002 study of fazirsiran for liver disease due to alpha-1 antitrypsin deficiency (AATD). Key findings include a 58% fibrosis regression in treated patients, an 83% median reduction in Z-AAT accumulation in the liver, and a 69% reduction in histologic globule burden. Fazirsiran aims to tackle AATD's liver manifestations, with plans for a Phase 3 study on the horizon. The collaboration has received Breakthrough Therapy and Orphan Drug designations from the FDA.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.59%
Tags
-
Rhea-AI Summary

Takeda has signed a 15-year lease with BioMed Realty for 600,000 square feet of R&D and office space in Kendall Square, Massachusetts. The new facility will enhance Takeda's research capabilities and support the company's shift towards flexible workspaces. Construction is set to begin in 2023, with occupation expected by 2026. This move aligns with Takeda's goal of achieving net-zero greenhouse gas emissions and reflects its commitment to innovation and sustainability while expanding its presence in a prominent life sciences hub.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.17%
Tags
none
Rhea-AI Summary

Takeda's dengue vaccine candidate TAK-003 has demonstrated significant efficacy, preventing 84% of hospitalizations and 61% of symptomatic dengue cases over 4.5 years. The results from the Phase 3 Tetravalent Immunization against Dengue Efficacy Study (TIDES) indicate no important safety risks. TAK-003 is currently under regulatory review for potential licensure in the European Union and select dengue-endemic countries. The study, involving over 20,000 children and adolescents, aims to address the urgent need for effective dengue prevention.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.22%
Tags
-
Rhea-AI Summary

Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) will present significant oncology data at the ASCO and EHA congresses in June. Key highlights include positive Phase 3 PARADIGM study results involving colorectal cancer in Japanese patients and survival data from the Phase 3 ECHELON-1 trial on Hodgkin lymphoma. Additionally, Takeda will showcase advancements in its pipeline targeting innate immunity for cancer treatment. These presentations reflect Takeda's commitment to improving patient care through innovation and collaboration in oncology.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.44%
Tags
none
-
Rhea-AI Summary

Moderna has announced that it will assume the role of marketing authorization holder for its COVID-19 vaccine Spikevax™ in Japan starting August 1, 2022. This transition includes taking over all related activities, such as import, regulatory compliance, development, quality assurance, and commercialization. In a collaborative effort, Takeda will continue to provide distribution support during a transitional phase of the national vaccination campaign. Both companies aim to ensure smooth operational implementation during this handover.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.44%
Tags
covid-19
Rhea-AI Summary

Moderna announces it will take over as the marketing authorization holder for its COVID-19 vaccine, SpikevaxTM, in Japan starting August 1, 2022. This transition from Takeda includes responsibilities for import, local regulations, development, quality assurance, and commercialization. Takeda will continue to provide distribution support during a transitional period. This move aims to strengthen Moderna's commercial organization in Japan as it continues to combat the COVID-19 pandemic.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.44%
Tags
covid-19

FAQ

What is the current stock price of Takeda Pharm (TAK)?

The current stock price of Takeda Pharm (TAK) is $14.06 as of February 21, 2025.

What is the market cap of Takeda Pharm (TAK)?

The market cap of Takeda Pharm (TAK) is approximately 43.9B.

What are Takeda Pharmaceutical's core therapeutic areas?

Takeda focuses on oncology, gastroenterology, neuroscience, rare diseases, and plasma-derived therapies.

Where is Takeda Pharmaceutical headquartered?

Takeda is headquartered in Tokyo, Japan.

What recent collaborations has Takeda Pharmaceutical entered into?

Takeda recently entered a joint venture with Astellas Pharma Inc. and Sumitomo Mitsui Banking Corporation to incubate early drug discovery programs.

How diversified is Takeda's revenue geographically?

Takeda's revenue is geographically diversified: 50% from the US, 20% from Japan, and 20% from Europe and Canada.

What was Takeda's revenue in fiscal 2023?

Takeda's revenue in fiscal 2023 was JPY 4.3 trillion.

Who can benefit from Takeda's new drug NBI-1065845?

NBI-1065845 is targeted at patients with major depressive disorder who have not benefited from at least one existing antidepressant treatment.

What is the focus of Takeda’s joint venture with Astellas and Sumitomo Mitsui?

The joint venture focuses on incubating early drug discovery programs to advance academic discoveries into practical medical treatments.

How long has Takeda been in the pharmaceutical industry?

Takeda has been a leader in the pharmaceutical industry for over two centuries.

In how many countries does Takeda operate?

Takeda operates in approximately 80 countries.

How does Takeda contribute to the field of major depressive disorder treatment?

Takeda collaborates with Neurocrine Biosciences to develop NBI-1065845, an investigational treatment showing positive Phase 2 results for MDD.
Takeda Pharm

NYSE:TAK

TAK Rankings

TAK Stock Data

43.94B
3.17B
0.01%
2.45%
0.12%
Drug Manufacturers - Specialty & Generic
Healthcare
Link
Japan
Tokyo